VantAI and TARA Biosystems Partner to Discover New Medicines

NEW YORK, NY - (EurekAlert) - VantAI and TARA Biosystems today announced the launch of a biology-driven, AI-enabled collaboration for accelerated cardiac drug development. The partnership will leverage TARA’s state-of-the-art in vitro human …

READ MORE

TARA Biosystems Report Study Results Demonstrating In Vitro Cardiac Biology Model Mimics Human Drug Response

NEW YORK, NY - (EurekAlert) - TARA Biosystems today reported study results demonstrating the ability of TARA’s in vitro human cardiac models to reproduce drug responses similar to those observed in humans. Appearing …

READ MORE

TARA Biosystems Announces $10 Million Series A2 Financing to Expand its Cardiac Disease Drug Discovery and Development Capabilities

NEW YORK, NY - (BUSINESS WIRE) - TARA Biosystems, Inc., a company generating in vitro human biology to increase the success of cardiac disease drug discovery and development, today announced a $10 million Series A2 …

READ MORE

TARA Biosystems Presents Translational Disease Models at Keystone Heart Failure Symposium

Tuesday March 3, 2020 – Keystone, Colorado.  TARA Biosystems Inc. today reported data showcasing its Biowire™ II as a platform for heart failure drug discovery.  Speaking at this year's Keystone

READ MORE

Heart-on-a-Chip Technology Predicts Preclinical Systolic and Diastolic in vivo Observations for Novel Cardiac Drug in Development

NEW YORK, NY - (Newswire.com) - TARA Biosystems, Inc. today reported in vivo and in vitro functional data from a

READ MORE